Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
2hon MSN
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
One quick online search or scroll through social media and you'll find an endless amount of weight loss advice. But it's hard ...
A new study breaks down exactly how to stop eating ultra-processed foods in eight weeks. Here's what it found and what ...
Fenugreek seeds can help you a lot in reducing obesity and belly fat. Fenugreek seeds have anti inflammatory properties that can help improve overall health. They speed up metabolism and reduce belly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback